+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Handwriting and speech changes across the levodopa cycle in Parkinson's disease



Handwriting and speech changes across the levodopa cycle in Parkinson's disease



Acta Psychologica 100(1-2): 71-84



Levodopa treatment is used to reduce rigidity and bradykinesia in Parkinson's disease (PD). This study tracked the handwriting and speech performance of 10 PD patients at 30-minute intervals across one levodopa drug cycle to evaluate levodopa-related changes in temporal and spatial measures that are assumed to correspond to changes in rigidity and bradykinesia. The handwriting measures included l and e upstroke duration and size. The speech measures included duration of the vowels /i/, /u/, /ae/, and /[symbol: see text]/ and the quadrilateral area produced by these vowels, and the slope of the diphthong /aI/. Levodopa significantly improved handwriting upstroke duration but not upstroke size. Speech measures did not show a significant trend across the levodopa cycle. The results suggest that upstroke duration is sensitive to the presumed effects of levodopa and that handwriting analysis may hold promise in helping to estimate an optimum levodopa regimen for PD patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 046211672

Download citation: RISBibTeXText

PMID: 9844557

DOI: 10.1016/s0001-6918(98)00026-2


Related references

Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease. International Journal of Speech-Language Pathology 12(5): 405-413, 2011

Effect of levodopa on handwriting tasks of different complexity in Parkinson's disease: a kinematic study. Journal of Neurology 2019, 2019

Effect of Levodopa on Speech Dysfluency in Parkinson's Disease. Movement Disorders Clinical Practice 6(2): 150-154, 2019

Speech dysfluency exacerbated by levodopa in Parkinson's disease. Movement Disorders 16(3): 562-565, 2001

For better or worse: The effect of levodopa on speech in Parkinson's disease. Movement Disorders 23(4): 574-580, 2008

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Bmj 311(7020): 1602-1607, 1995

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. Bmj 307(6902): 469-472, 1993

Levodopa-induced alterations in speech rate in advanced Parkinson's disease. Acta Neurologica Belgica 106(1): 19-22, 2006

Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease. Cureus 10(7): E2986, 2018

Levodopa effects on hand and speech movements in patients with Parkinson's disease: a FMRI study. Plos One 7(10): E46541, 2013

Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission. Journal of Voice 25(4): E199-E205, 2011

Impact of Parkinson's disease and levodopa on resting state functional connectivity related to speech prosody control. Parkinsonism and Related Disorders 22 Suppl 1: S52-S55, 2016

Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clinical Neuropharmacology 36(3): 84-91, 2014

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. Journal of Neural Transmission 117(3): 333-342, 2010

Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination. Neurologia 20(4): 180-188, 2005